Lelima Pharma SRL
Lelima Pharma reported total assets of €1.29m at the end of the 2026 financial year (annual accounts filed with the NBB on 21 Sep 2026).
The score of Lelima Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2026
Change 2023 → 2026: Equity +142 % Total assets +981 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Lelima Pharma's annual accounts
Filed annual accounts
- Year ended 31 Mar 2026filed on 21 Sep 2026
- Year ended 31 Mar 2025filed on 29 Sep 2025
- Year ended 31 Mar 2024filed on 30 Oct 2024
- Year ended 31 Mar 2023filed on 31 Oct 2023
- Year ended 31 Mar 2022filed on 24 Aug 2022
Lelima Pharma's financial analysis
- Solvency19.2%sector median: 49.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Lelima Pharma
Lelima Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0691.649.590
- VAT number
- BE0691649590
- Peppol
- Registered · 0208:0691649590 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 01 Mar 2018
- Registered office
- 1341 Ottignies-Louvain-la-Neuve
- Latest accounts
- 2026 · filed on 21 Sep 2026
- Activity
- Business and other management consultancy activities (NACE 70200)
Lelima Pharma (SRL) has been based in Ottignies-Louvain-la-Neuve since 2018, active in: business and other management consultancy activities. For 2026, it reports a net profit of 54,519 € and equity of 247,899 €; its revenue is not published. Its solvency stands at 19.2%, below the median of its sector (49.1%).
Companies similar to Lelima Pharma
Companies in the same business, of comparable size and area, outside its group.
- Redvik Business and other management consultancy activities Beveren-Kruibeke-Zwijndrecht · balance sheet €1.29m
- Notarion Business and other management consultancy activities Liège · balance sheet €1.29m
- FGCM Business and other management consultancy activities Waterloo · balance sheet €1.30m
- XMP Consulting Business and other management consultancy activities Lasne · balance sheet €1.30m
- Nijasu Business and other management consultancy activities Theux · balance sheet €1.29m
- Marnell-CAB Business and other management consultancy activities Braine-le-Château · balance sheet €1.30m
- Galwico Business and other management consultancy activities Tongeren-Borgloon · balance sheet €1.29m
- Retail LMC Business and other management consultancy activities Étalle · balance sheet €1.34m
Frequently asked questions about Lelima Pharma
What is the revenue of Lelima Pharma?
Lelima Pharma files its accounts in a format where revenue is optional: it is not published for 2026.
What is the VAT number of Lelima Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0691649590 for Lelima Pharma, if the company is VAT-registered. Its company number (CBE) is 0691.649.590.
Where is the registered office of Lelima Pharma?
According to the CBE register, the registered office of Lelima Pharma is in 1341 Ottignies-Louvain-la-Neuve.
What is the equity of Lelima Pharma?
At the close of the 2026 financial year, the equity of Lelima Pharma amounts to 247,899 €, a solvency of 19.2% of total assets.
Who manages Lelima Pharma?
The register lists 1 active mandates at Lelima Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Lelima Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →